Trius prices $29.9M offering; NICE calls for exposing trial data;

 @FierceBiotech: NuPathe jumps on FDA's OK for migraine drug. News | Follow @FierceBiotech

@JohnCFierce: VC ends '12 on a high note, outlook ranges from tough to terrific. More | Follow @JohnCFierce

@RyanMFierce: Does anyone know how much total funding (VC, corp., foundation) went into biotech? Still, $800M off in 2012 from '11 on the VC front. Yikes. | Follow @RyanMFierce

> Trius Therapeutics ($TSRX), which has a lead antibiotic against MRSA in Phase III development, has priced shares for a public offering worth $29.9 million. Release

> The U.K. drug-pricing watchdog NICE is likely to encounter resistance from pharma with its call for all clinical trial data to be published. Article | More

> With tech from the University of Miami, Biscayne Pharmaceuticals has grabbed a $1.5 million financing to research new growth hormone drugs. Release

Medical Device News

 @FierceMedDev: Medical device VC cash plunged 13% in 2012. Report | Follow @FierceMedDev

 @DamianFierce: So, is $LIFE looking to sell itself? This PR is ominous. Release | Follow @DamianFierce

> Trauson's shares jump 41% on news of Stryker's $764M offer. Item

> GI Dynamics launches trial targeting FDA approval. Story

> FDA wants feedback on tighter hip-implant regs. News

Pharma News

@FiercePharma: Not as good for branded pharma, CHMP also OK'd generic versions of Forest's Namenda + Boehringer's Micardis. More | Follow @FiercePharma

 @AlisonBFierce: Roche said U.S. regulators will allow it to begin selling the company's reserve stock of adult Tamiflu capsules. News | Follow @AlisonBFierce

@EricPFierce: Costco jumps into pharmacy benefits, bringing a new player to the table for drug companies to think about. Report | Follow @EricPFierce

> Pfizer's Bosulif set for greater sales with EMA approval. Article

> Pfizer sets share price for animal health spinoff. Report

> FTC says pay-to-delay getting worse; GpHA says nonsense. News

And Finally… Acorda Therapeutics ($ACOR) CEO Ron Cohen wants the U.S. to alter its tax code to cater to biotech investment. Forbes column

 

 

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.